IMRN
Immuron Limited
stockNASDAQADR
immuron ltd is a publicly listed australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. immuron's technology platform is capable of developing and producing an orally stable therapeutic as a potential 'oral targeted therapy' for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (nash) diabetes, colitis, arthritis, inflammatory bowel diseases (ibd), irritable bowel syndrome (ibs), liver fibrosis and other chronic disorders in which the immune system plays a key role in thier pathogenesis. these disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile. immuron has one marketed product, which provides proof of concept for its oral immune technology platform, and a pipeline of products at various stages of cl
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1M | 1.24 | 2026-09-21 | -16.93% | 0.654 |
| 3M | 1.22 | 2026-07-21 | -15.57% | -0.615 |
| 6M | 0.93 | 2026-04-21 | +11.13% | 0.308 |
| 1Y | 2.27 | 2025-10-21 | -54.52% | 0.558 |
| 2Y | 1.96 | 2024-10-21 | -47.45% | — |
| 5Y | 3.61 | 2021-10-21 | -71.47% | -0.030 |
Immuron Limited (NASDAQ:IMRN) stock price today is $1.03, and today's volume is 7,379. IMRN is up 0.980% today. The 30 day average volume is 138,271. IMRN market cap is $8.31M with 8.07M shares outstanding.